Certified Advisory Corp
AVIR icon

Certified Advisory Corp’s Atea Pharmaceuticals AVIR Stock Holding History

Certified Advisory Corp’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$128K Hold
24,500
– – 0.01% 326
2026
Q2 		$114K Hold
24,500
– – 0.01% 325
2026
Q1 		$132K Hold
24,500
– – 0.01% 315
2025
Q4 		$87.5K Hold
24,500
– – 0.01% 316
2025
Q3 		$71K Buy
+24,500
New +$83.7K 0.01% 313

Other funds holding AVIR

Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Auour Investments
Auour Investments Woburn, Massachusetts $353M AUM 8.66% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Sunpointe
Sunpointe St. Louis, Missouri $328M AUM 26.96% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Blue Trust Inc
Blue Trust Inc Alpharetta, Georgia $9.5B AUM 13.02% 1-Year Est. Return

Certified Advisory Corp's AVIR Position: Q3 2026 in Review

Certified Advisory Corp held its Atea Pharmaceuticals (AVIR) position steady in Q3 2026 at 24,500 shares worth $128K. The position accounts for 0.01% of the portfolio, ranked #326.

Certified Advisory Corp first reported a position in AVIR in Q3 2025 and has held it in 5 quarters since. The position peaked at $132K in Q1 2026. 28 funds tracked by Wall St. Rank hold AVIR as of Q3 2026.

  • Certified Advisory Corp held 24,500 shares of Atea Pharmaceuticals worth $128K as of Q3 2026.
  • Certified Advisory Corp left its Atea Pharmaceuticals share count unchanged in Q3 2026.
  • Atea Pharmaceuticals made up 0.01% of Certified Advisory Corp's portfolio in Q3 2026, its #326 holding.
  • Certified Advisory Corp first reported a position in Atea Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • Certified Advisory Corp's Atea Pharmaceuticals position peaked at $132K in Q1 2026.
  • 28 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2026.

Based on Certified Advisory Corp's 13F filing for Q3 2026, filed 29 Oct 2026.